“We still have great confidence in this investment, and we intend to stay on as a long term majority owner in the Company” says managing partner Gert W. Munthe in Herkules Capital. Mr. Munthe is also chairman of the board at Pronova. Herkules bought 100% of Pronova in January 2004, and listed the company at Oslo Stock Exchange in October 2007. During this process Herkules’ ownership was reduced to 58.4%. The price of the shares was set through a book building process managed by Carnegie ASA and SEB Enskilda AS. The shares were sold at a price of NOK 18.50 per share.
Total realized proceeds from this sale were NOK 461.4 million. To date the Pronova investment has generated proceeds of NOK 4,133.8 million, with a remaining Herkules’ ownership share of 50.01%.
Contact:
Gert W. Munthe, Managing partner at Herkules Capital and Chairman of the board at Pronova BioPharma ASA
Mob: +47 92 02 23 63
Rikke Reinemo, Director at Herkules Capital and member of the board at Pronova BioPharma ASA
Mob: +47 97 02 87 82